A research team hands you a clinical study and says: "This supports our new product claim." You open a PDF full of statistical tables, p-values, and endpoint terminology. Your job is to decide whether the claim is defensible, but you were not trained to read research papers.
This situation is common across consumer health, supplement, cosmetics, and food brands. Marketing teams and founders regularly need to evaluate clinical evidence without the scientific background to parse it fully. The good news is that making this evaluation well does not require becoming a scientist. It requires knowing which five sections of a study determine how strong a claim can be, and how to read each one through a commercial lens.
The connection between clinical research and marketing language is not direct. A study does not come with a pre-approved claim attached. The path from research to claim requires a series of interpretive decisions, and each one carries compliance and commercial risk if made incorrectly.
The sequence that connects evidence to consumer messaging works like this:
Marketing teams that skip this sequence and move directly from "study shows positive result" to "claim approved" consistently create two problems: overclaiming that creates regulatory exposure, and underdifferentiated claims that do not leverage what the evidence actually demonstrates.
For more on how those mistakes compound in regulated industries, our overview of common food regulatory compliance mistakes in packaging covers the most frequent patterns.
The research question is the frame for everything else in the study. Before evaluating results, understand exactly what the researchers set out to test, because the conclusions drawn can only address what was actually studied.
Three questions to answer from the study's introduction and methods sections:
A study testing a specific extract at a specific dose in adults over 50 with mild joint discomfort produces evidence that is specific to those conditions. Applying it to a broader population or a different formulation requires additional justification, not just a positive headline result.
Study design determines how confidently findings can be translated into marketing language. This is the single most important factor for how to evaluate clinical studies from a claim development perspective.
Different designs produce different levels of confidence, and that confidence directly maps to the strength of claim language the evidence can support.
A randomized controlled trial (RCT) randomly assigns participants to a treatment group or a control group. Random assignment reduces the risk that pre-existing differences between participants explain the results rather than the treatment itself.
RCTs, particularly those with a placebo control and blinding, provide the strongest basis for direct product efficacy claims. Language like "clinically shown to" or "demonstrated in a clinical study to" is typically supported by this design when the other study quality factors are also strong.
When participants in a control group receive a placebo rather than no treatment at all, the study can detect the specific effect of the treatment beyond the placebo response, which is substantial in many health categories. When neither participants nor researchers know who received the treatment (double-blind design), the risk of conscious or unconscious bias affecting results is further reduced.
Blinding matters for claim development because it affects how much confidence can be placed in the magnitude of the measured effect. A non-blinded study that shows a positive result requires more qualified claim language than a double-blind study showing the same result.
Observational studies track what happens to groups of people without assigning them to any treatment. They can show associations between a behavior or exposure and an outcome, but they generally cannot establish that one caused the other.
A survey showing that people who report consuming a specific ingredient also report better sleep does not prove the ingredient improves sleep. Consumer-facing claims cannot typically be derived directly from observational data without appropriate qualification.
Preclinical research, conducted in cell cultures or animal models, informs scientific understanding of how an ingredient might work. It cannot directly support consumer product claims. A cell study showing that a compound affects a biological pathway in vitro does not provide a basis for marketing the product as producing that effect in humans.
Endpoints are the specific outcomes the study measured. Understanding endpoints is one of the most practical clinical research skills for marketers, because the endpoint is what determines whether a claim describes a real consumer benefit or an indirect biological measurement.
The primary endpoint is the outcome the study was designed to detect. Statistical power, sample size, and study duration are all calculated to give the study a reasonable chance of detecting a meaningful change in this specific outcome.
Claims built on primary endpoint results are the strongest available from a study. If the primary endpoint was not met, no secondary results can rescue the study as the basis for a strong efficacy claim.
Secondary endpoints are additional measurements collected during the study. They may provide useful supporting information, but they were not the focus of the study's design and their results carry more uncertainty.
Marketers frequently build claims on secondary endpoint results because the primary finding may be less commercially appealing. This creates compliance risk: secondary results from a study not powered to detect them are exploratory, not conclusive. Claim language for secondary findings requires qualification.
A biomarker is a measurable indicator of a biological process: a blood level, an enzyme activity, an inflammatory marker. A consumer outcome is something a person experiences: less discomfort, better energy, improved performance.
Many studies measure biomarkers rather than consumer outcomes because biomarkers are easier to measure objectively. A study showing improvement in a biomarker does not automatically support a claim about the consumer experience the biomarker is associated with. Translating a biomarker result into a consumer benefit claim requires additional validation and careful qualification.
Sample size affects how reliably the study results represent what would happen across a broader population. This is particularly relevant for how to evaluate clinical studies when deciding which findings can support consumer-facing marketing language.
A study of 20 participants that shows a significant result may be promising, but the finding carries more uncertainty than a study of 300 participants showing the same result. Small studies are more likely to show a positive result by chance, and their confidence intervals (the statistical range within which the true effect likely falls) are wider.
For claim development purposes, a small study result typically supports more qualified language: "shown in a preliminary study" or "shown in an initial clinical study" rather than "clinically proven."
Participant characteristics determine whether findings apply to the intended consumer. A study conducted entirely in men cannot directly support a claim targeting women. A study in adults with a specific health condition cannot directly support a general population claim.
Read the study's inclusion and exclusion criteria carefully. If the participant profile does not match the target consumer, the claim requires either additional evidence or explicit population qualification.
A study running for four weeks cannot support claims about long-term benefits. If the study measured a short-term effect and the claim implies ongoing benefit, the duration mismatch creates an implied overclaim.
For our broader look at how claims and packaging interact with compliance expectations over time, see our guide on the importance of labeling compliance and its impact on your business.
Dosage alignment is one of the most overlooked factors in clinical research for marketers. A study can be well-designed, large, and highly relevant, and still not support a claim for a product that delivers the ingredient differently or at a different dose.
If a study tested 500mg of an ingredient and the product contains 250mg, the product delivers half the studied dose. The study may still be relevant as supporting evidence, but it cannot directly support efficacy claims based on the full-dose result.
Bioavailability, the proportion of an ingredient that enters circulation and produces an effect, varies significantly between delivery formats. An ingredient tested in a capsule may not behave identically in a beverage, powder, or topical application. Format differences require either format-specific research or qualified claim language.
When products contain multiple active ingredients, but studies examine only one, the study cannot directly support claims about the combined formula. The presence of other ingredients may enhance, reduce, or simply be irrelevant to the studied ingredient's effect, but that remains unverified without combination-specific research.
For background on how ingredient claims work alongside labeling requirements, our guide on how to verify food ad ingredient claims effectively covers the practical framework.
Once you have worked through the five factors above, you can map findings to claim categories. This is the practical output of how to read a clinical study as a marketer.
Claims a study may support:
Claims the same study likely does not support:
The wording test: read the claim out loud and ask whether each word is traceable to a specific finding in the study. If a word adds meaning not directly supported by the evidence, revise or remove it.
For teams ready to move from study evaluation to claim drafting, our step-by-step guide on how to build science-backed product claims covers the full translation process.
Reading a clinical study as a marketer or founder means working through five questions in sequence: What was the study testing? How strong is the design? What did the study actually measure? How many people were studied and who were they? Does the product match the study conditions?
Those five questions determine what you can say, and what you cannot say, about a product's clinical evidence. The quality of that evaluation directly determines the defensibility of every claim that follows.
The best marketing claims do not come from finding positive research. They come from accurately understanding what specific research demonstrates, and translating that understanding into language consumers can act on.
Upload your label artwork and claim copy to GetGenAI for an automated compliance review against current regulatory standards before production.
What part of a clinical study should marketers read first when evaluating claim potential?
Start with the abstract, which summarizes the study question, design, and primary results in a few paragraphs. Then go directly to the methods section to understand study design, sample size, participant characteristics, and endpoint definitions. Finally, read the results section for primary endpoint findings. The discussion section contains the researchers' interpretation, which is useful context but should not substitute for reading the actual results.
Can a small clinical study still support a product claim?
Yes, with appropriate qualification. A small study showing a significant result supports language like "shown in a preliminary clinical study" or "demonstrated in an initial study." It does not support "clinically proven" or language implying consistent results across a broad population. The key is matching the claim language to the confidence level the evidence actually supports, not to the level the brand would prefer.
How do marketers evaluate whether a competitor's clinical study applies to their product?
Apply the same five-factor evaluation: does your product use the same ingredient, at the same dose, in the same delivery format, for the same target population, as what the study tested? If the answer is yes across all five factors, the evidence may be applicable with appropriate reference. If any factor differs materially, the competitor's study provides indirect support at best and requires your own research or more qualified claim language.
Get intels on brand, platform, and regulatory changes, distilled by our compliance team
